Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Metagenomi (MGX) to $16 from $20 on updated model assumption, while keeping an Overweight rating on the shares. The firm notes updated NHP data from the Hem A program demonstrate stable FVIII levels out to 19 months, boding well for a differentiated product profile and also providing preclinical validation for the secreted protein platform.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGX:
- Metagenomi’s Promising Gene Editing Advancements and Strategic Growth Drive Buy Rating
- Metagenomi, Inc. Reports Q1 2025 Financial Results
- Metagenomi reports Q1 EPS (68c), consensus (51c)
- Metagenomi sees cash, equivalents supporting operations into 2027
- Metagenomi price target lowered to $7 from $14 at H.C. Wainwright